20. September 2024 – Hevolution Foundation and Dolby Family Ventures joined ND Capital as additional institutional investors bringing Series A funding in Vandria to a total of $30.7M. Vandria’s lead CNS compound VNA-318 is a mitophagy inducer about to enter clinical development with a unique dual mode of action of immediate improvement of cognitive function paired with long-term disease-modifying effects.

Walder Wyss advised Vandria SA on this round of financing. The team was led by Luc Defferrard (Partner, Corporate/M&A) and included Ken Savioz (Associate, Corporate/M&A) and Anaïs Essinger (Associate, Corporate/M&A).